Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Humacyte, Inc.HUMA · Entity 6478 | Director | May 15, 2024 | May 15, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Humacyte, Inc.
Report date May 15, 2024 · Filed May 15, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy the Binder Trust dated 15 July 2003 | 50,000 |
Reported balance
After 2024-05-15 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2024-05-15 · Purchase · Acquired 50,000 · Balance 50,000 F1: The price is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $6.44 to $6.59. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. |
| Common StockSEC Table I · non-derivative | Direct | 160,000 |
Reported balance
After 2024-05-15 transaction · row 2
1 source rowRow 2 · 2024-05-15 · Purchase · Acquired 50,000 · Balance 160,000 F2: The price is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $6.64 to $6.96. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The price is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $6.44 to $6.59. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F2: The price is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $6.64 to $6.96. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 15, 2024 Filed May 15, 2024 23:24 UTC | Humacyte, Inc. HUMA · Entity 6478 | PurchaseCommon Stock | 50,000 | $6.78 | $339,000.00 |
DisclosureSEC source: 0001818382-24-000058 · wk-form4_1715815434.xml · nonDerivative · entry 2 Binder Gordon M · CIK 0001291957 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 160,000 F2 · price: The price is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $6.64 to $6.96. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| May 15, 2024 Filed May 15, 2024 23:24 UTC | Humacyte, Inc. HUMA · Entity 6478 | PurchaseCommon Stock | 50,000 | $6.57 | $328,500.00 |
DisclosureSEC source: 0001818382-24-000058 · wk-form4_1715815434.xml · nonDerivative · entry 1 Binder Gordon M · CIK 0001291957 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By the Binder Trust dated 15 July 2003 Disclosed balance after: 50,000 F1 · price: The price is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $6.44 to $6.59. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| June 15, 2023 Filed Jun 16, 2023 20:10 UTC | Humacyte, Inc. HUMA · Entity 6478 | GrantStock Options (right to buy) · Derivative | 8,500 | $0.00 Strike: $3.35 | $0.00 |
DisclosureSEC source: 0001818382-23-000088 · wf-form4_168694623409421.xml · derivative · entry 1 Binder Gordon M · CIK 0001291957 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,500 Underlying: Common Stock · 8,500 shares Expires 2033-06-15 F1 · derivative.exercise_date: The first 25% of the option becomes exercisable on June 15, 2024, after which 1/48 of the option will become exercisable on the 15th of each month through June 15, 2027. Read SEC document |
| September 02, 2022 Filed Sep 6, 2022 20:14 UTC | Humacyte, Inc. HUMA · Entity 6478 | PurchaseCommon Stock | 61,841 | $4.40 | $272,100.40 |
DisclosureSEC source: 0001818382-22-000119 · wf-form4_166249526500566.xml · nonDerivative · entry 1 Binder Gordon M · CIK 0001291957 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,000 F1 · price: The shares were purchased in multiple transactions at per share prices ranging from $4.20 to $4.70. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| September 01, 2022 Filed Sep 1, 2022 21:28 UTC | Humacyte, Inc. HUMA · Entity 6478 | PurchaseCommon Stock | 48,159 | $4.00 | $192,636.00 |
DisclosureSEC source: 0001818382-22-000117 · wf-form4_166206771163271.xml · nonDerivative · entry 1 Binder Gordon M · CIK 0001291957 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,159 F1 · price: The shares were purchased in multiple transactions at per share prices ranging from $3.53 to $4.20. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| June 09, 2022 Filed Jun 13, 2022 20:24 UTC | Humacyte, Inc. HUMA · Entity 6478 | GrantStock Options (right to buy) · Derivative | 8,500 | $0.00 Strike: $4.34 | $0.00 |
DisclosureSEC source: 0001818382-22-000097 · wf-form4_165515180978252.xml · derivative · entry 1 Binder Gordon M · CIK 0001291957 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,500 Underlying: Common Stock · 8,500 shares Expires 2032-06-09 F1 · derivative.exercise_date: The first 25% of the option becomes exercisable on June 9, 2023, after which 1/48 of the option will become exercisable on the 9th of each month through June 9, 2026. Read SEC document |
| October 13, 2021 Filed Oct 15, 2021 19:43 UTC | Humacyte, Inc. HUMA · Entity 6478 | GrantStock Options (right to buy) · Derivative | 13,000 | $0.00 Strike: $10.03 | $0.00 |
DisclosureSEC source: 0001104659-21-126721 · tm2130120-1_4seq1.xml · derivative · entry 1 Binder Gordon M · CIK 0001291957 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 13,000 shares Expires 2031-10-13 F1 · derivative.exercise_date: The first 25% of the option becomes exercisable on October 13, 2022, after which 1/36 of the option will become exercisable on the 13th of each month through October 13, 2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.